UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 28, 2007
Targeted Genetics Corporation
(Exact name of registrant as specified in its charter)
| | | | | |
Washington | | 0-23930 | | 91-1549568 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
1100 Olive Way, Suite 100, Seattle, Washington | | 98101 |
| (Address of principal executive offices) | | (Zip Code) |
| Registrant’s telephone number, including area code | | (206) 623-7612 |
Not Applicable
(Former name or former address if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On February 28, 2007, Targeted Genetics Corporation announced that Dr. Jan van Lunzen, Medical Director, University Medical Center, Hamburg Eppendorf, Germany, presented updated Phase I data from a study of tgAAC09 in healthy volunteers not infected with HIV in a poster presentation at the 14th Conference on Retroviruses and Opportunistic Infections in Los Angeles.
A copy of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits:
| | | |
| 99.1 | | Press Release of Targeted Genetics Corporation dated February 28, 2007 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | TARGETED GENETICS CORPORATION |
| | | |
| | | |
| | By: | /s/ David J. Poston |
| | | David J. Poston |
| | | Vice President Finance and Chief Financial Officer |
| |
Dated: February 28, 2007
INDEX TO EXHIBITS
| | | |
| 99.1 | | Press Release of Targeted Genetics Corporation dated February 28, 2007 |
